Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bedside to bench: interfering with leukemic stem cells.

Literature DB >> 18463658

Bedside to bench: interfering with leukemic stem cells.

Daniela S Krause, Richard A Van Etten.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2008 PMID： 18463658 PMCID： PMC3490184 DOI： 10.1038/nm0508-494

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

14 in total

Review 1. Focus on myeloproliferative diseases and myelodysplastic syndromes.

Authors: Richard A Van Etten; Kevin M Shannon
Journal: Cancer Cell Date: 2004-12 Impact factor: 31.743

Review 2. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

Authors: Chloé James; Valérie Ugo; Nicole Casadevall; Stefan N Constantinescu; William Vainchenker
Journal: Trends Mol Med Date: 2005-11-03 Impact factor: 11.951

3. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.

Authors: Richard T Silver
Journal: Cancer Date: 2006-08-01 Impact factor: 6.860

4. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.

Authors: F Pane; I Mostarda; C Selleri; R Salzano; A M Raiola; L Luciano; G Saglio; B Rotoli; F Salvatore
Journal: Blood Date: 1999-10-01 Impact factor: 22.113

5. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.

Authors: M Schmidt; A Hochhaus; A Nitsche; R Hehlmann; A Neubauer
Journal: Blood Date: 2001-06-01 Impact factor: 22.113

6. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

Authors: Jean-Jacques Kiladjian; Bruno Cassinat; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Marie-Laurence Menot; Gerald Massonnet; Jean-Luc Dutel; Kamel Ghomari; Philippe Rousselot; Marie-Jose Grange; Yasmina Chait; William Vainchenker; Nathalie Parquet; Lina Abdelkader-Aljassem; Jean-François Bernard; Jean-Didier Rain; Sylvie Chevret; Christine Chomienne; Pierre Fenaux
Journal: Blood Date: 2006-05-18 Impact factor: 22.113

7. Dynamics of chronic myeloid leukaemia.

Authors: Franziska Michor; Timothy P Hughes; Yoh Iwasa; Susan Branford; Neil P Shah; Charles L Sawyers; Martin A Nowak
Journal: Nature Date: 2005-06-30 Impact factor: 49.962

Review 8. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

Authors: M Copland; A R Fraser; S J Harrison; T L Holyoake
Journal: Cancer Immunol Immunother Date: 2004-11-30 Impact factor: 6.968

9. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.

Authors: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis J Giles; Mary Beth Rios; Stefan H Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Journal: Cancer Date: 2003-02-15 Impact factor: 6.860

10. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.

Authors: Giuliana Alimena; Massimo Breccia; Luigia Luciano; Fabrizio Quarantelli; Daniela Diverio; Barbara Izzo; Biagio De Angelis; Marco Mancini; Roberto Latagliata; Ida Carmosino; Mauro Nanni; Marco Picardi; Bruno Rotoli; Franco Mandelli; Fabrizio Pane
Journal: Leuk Res Date: 2007-08-10 Impact factor: 3.156

5 in total

Bedside to bench: interfering with leukemic stem cells.

Review 1. Focus on myeloproliferative diseases and myelodysplastic syndromes.

Review 2. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

3. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.

4. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.

5. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha.

6. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

7. Dynamics of chronic myeloid leukaemia.

Review 8. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

9. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.

10. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.

Review 1. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

Review 2. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

3. IFN-alpha wakes up sleeping hematopoietic stem cells.

4. Toward a cure for chronic myeloid leukemia.

Review 5. Navigating the road toward optimal initial therapy for chronic myeloid leukemia.